In a boon for buyer Bristol-Myers, Celgene's JAK med Inrebic scores FDA nod
admin 16th August 2019 Uncategorised 0Bristol-Myers Squibb’s $74 billion Celgene takeover has been a roller coaster, with some Revlimid patent wins on the upside and, on the down, an FTC-forced sale of blockbuster Otezla. But the FDA just handed the merger partners another win.
More: In a boon for buyer Bristol-Myers, Celgene's JAK med Inrebic scores FDA nod
Source: fierce